Daniel Bruetman

758 total citations
16 papers, 530 citations indexed

About

Daniel Bruetman is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Daniel Bruetman has authored 16 papers receiving a total of 530 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 3 papers in Molecular Biology. Recurrent topics in Daniel Bruetman's work include Lung Cancer Treatments and Mutations (11 papers), Lung Cancer Research Studies (10 papers) and Lung Cancer Diagnosis and Treatment (5 papers). Daniel Bruetman is often cited by papers focused on Lung Cancer Treatments and Mutations (11 papers), Lung Cancer Research Studies (10 papers) and Lung Cancer Diagnosis and Treatment (5 papers). Daniel Bruetman collaborates with scholars based in United States. Daniel Bruetman's co-authors include Nasser H. Hanna, William B. Fisher, Ramaswamy Govindan, Rafat Ansari, Cynthia S. Johnson, Constantin T. Yiannoutsos, N. M. Chowhan, Donald Richards, Sreenivasa Nattam and Tim Breen and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Molecular Cancer Therapeutics.

In The Last Decade

Daniel Bruetman

15 papers receiving 521 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel Bruetman United States 7 462 317 63 61 49 16 530
M. R. Green United States 12 524 1.1× 414 1.3× 52 0.8× 26 0.4× 101 2.1× 15 674
Angela White United States 6 383 0.8× 287 0.9× 57 0.9× 49 0.8× 38 0.8× 8 464
Qiang Lin China 12 211 0.5× 136 0.4× 43 0.7× 51 0.8× 57 1.2× 46 333
Bryan Chang United States 9 201 0.4× 303 1.0× 72 1.1× 69 1.1× 32 0.7× 23 457
Samir Darwish Italy 12 311 0.7× 250 0.8× 30 0.5× 15 0.2× 116 2.4× 17 441
Daizo Kishino Japan 12 353 0.8× 367 1.2× 47 0.7× 6 0.1× 124 2.5× 39 555
Jacky Créquit France 9 306 0.7× 229 0.7× 37 0.6× 7 0.1× 39 0.8× 18 368
Britta Lödén Sweden 8 166 0.4× 121 0.4× 47 0.7× 47 0.8× 26 0.5× 15 254
Rizvan Mamet United States 6 240 0.5× 213 0.7× 52 0.8× 25 0.4× 33 0.7× 9 433

Countries citing papers authored by Daniel Bruetman

Since Specialization
Citations

This map shows the geographic impact of Daniel Bruetman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Bruetman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Bruetman more than expected).

Fields of papers citing papers by Daniel Bruetman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Bruetman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Bruetman. The network helps show where Daniel Bruetman may publish in the future.

Co-authorship network of co-authors of Daniel Bruetman

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Bruetman. A scholar is included among the top collaborators of Daniel Bruetman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Bruetman. Daniel Bruetman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Hamilton, Erika, Alberto Bessudo, Daniel Bruetman, et al.. (2018). Results from a phase I study of andecaliximab in combination with paclitaxel in patients with previously untreated metastatic breast cancer.. Journal of Clinical Oncology. 36(15_suppl). 1032–1032. 1 indexed citations
2.
Starodub, Alexander, Mohammed Milhem, Kenneth Pennington, et al.. (2013). Phase I study of TH-302, investigational hypoxia-targeted drug, in combination with sunitinib.. Journal of Clinical Oncology. 31(15_suppl). e15557–e15557. 2 indexed citations
3.
Starodub, Alexander, Daniel A. Vaena, Kenneth Pennington, et al.. (2013). Abstract B77: Phase I study of TH-302, an investigational hypoxia-targeted drug, in combination with sunitinib.. Molecular Cancer Therapeutics. 12(11_Supplement). B77–B77. 2 indexed citations
4.
5.
Jalal, Shadia I., Rafat Ansari, Ramaswamy Govindan, et al.. (2009). Pemetrexed in Second Line and beyond Small Cell Lung Cancer: A Hoosier Oncology Group Phase II Study. Journal of Thoracic Oncology. 4(1). 93–96. 25 indexed citations
6.
Fisher, William B., Daniel Bruetman, J. McClean, et al.. (2008). Gefitinib Plus Celecoxib in Chemotherapy-Naïve Patients with Stage IIIB/IV Non-small Cell Lung Cancer: A Phase II Study from the Hoosier Oncology Group. Journal of Thoracic Oncology. 3(4). 374–379. 19 indexed citations
7.
8.
Hanna, Nasser H., Marcus A. Neubauer, Constantin T. Yiannoutsos, et al.. (2008). Phase III Study of Cisplatin, Etoposide, and Concurrent Chest Radiation With or Without Consolidation Docetaxel in Patients With Inoperable Stage III Non–Small-Cell Lung Cancer: The Hoosier Oncology Group and U.S. Oncology. Journal of Clinical Oncology. 26(35). 5755–5760. 341 indexed citations
9.
10.
11.
12.
Güleç, Seza A., Kenneth Pennington, Daniel Bruetman, et al.. (2007). A phase-I study of 90Y-hPAM4 (humanized anti-MUC1 monoclonal antibody) in patients with unresectable and metastatic pancreatic cancer. 48. 4 indexed citations
13.
Hanna, Nasser H., Rafat Ansari, Sumeet Bhatia, et al.. (2006). Pemetrexed in patients (pts) with relapsed small cell lung cancer (SCLC): A phase II study from the Hoosier Oncology Group. Journal of Clinical Oncology. 24(18_suppl). 7063–7063. 12 indexed citations
14.
Einhorn, Lawrence H., William B. Fisher, Daniel Bruetman, et al.. (2006). Gefitinib plus celecoxib in chemotherapy-naïve patients with stage IIIB/IV non-small cell lung cancer (NSCLC): A phase II study from the Hoosier Oncology Group. Journal of Clinical Oncology. 24(18_suppl). 7066–7066. 4 indexed citations
15.
16.
Bruetman, Daniel, et al.. (1991). Differentiating agents in malignant disease. Medical and Pediatric Oncology. 19(2). 71–83.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by M. R. Green Breakdown of academic impact, for papers by Angela White Breakdown of academic impact, for papers by Qiang Lin Breakdown of academic impact, for papers by Bryan Chang Breakdown of academic impact, for papers by Samir Darwish Breakdown of academic impact, for papers by Daizo Kishino Breakdown of academic impact, for papers by Jacky Créquit Breakdown of academic impact, for papers by Britta Lödén Breakdown of academic impact, for papers by Rizvan Mamet
Rankless by CCL
2026